External Validation of the ELAPSS Score for Prediction of Unruptured Intracranial Aneurysm Growth Risk by van Kammen, Mayte Sanchez et al.
Copyright © 2019  Korean Stroke Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which 
permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN: 2287-6391 • eISSN: 2287-6405
Original Article
Journal of Stroke 2019;21(3):340-346
https://doi.org/10.5853/jos.2019.01277
340 http://j-stroke.org
External Validation of the ELAPSS Score for Prediction 
of Unruptured Intracranial Aneurysm Growth Risk
Mayte Sánchez van Kammen,a Jacoba P. Greving,b Satoshi Kuroda,c Daina Kashiwazaki,c Akio Morita,d 
Yoshiaki Shiokawa,e Toshikazu Kimura,f Christophe Cognard,g Anne C. Januel,g Antti Lindgren,h  
Timo Koivisto,h Juha E. Jääskeläinen,h,i Antti Ronkainen,j Liisa Pyysalo,j Juha Öhman,j Melissa Rahi,k  
Johanna Kuhmonen,k Jaakko Rinne,k Eva L. Leemans,l,m Charles B. Majoie,l W. Peter Vandertop,n  
Dagmar Verbaan,n Yvo B.W.E.M. Roos,o René van den Berg,l Hieronymus D. Boogaarts,p Walid Moudrous,p 
Ido R. van den Wijngaard,q,r Laura ten Hove,s Mario Teo,t Edward J. St George,t Katharina A.M. Hackenberg,u 
Amr Abdulazim,u Nima Etminan,u Gabriël J.E. Rinkel,a Mervyn D.I. Vergouwena
aDepartment of Neurology and Neurosurgery, University Medical Centre Utrecht, Utrecht, the Netherlands
bJulius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands
cDepartment of Neurosurgery, University of Toyama, Toyama, Japan
dDepartment of Neurological Surgery, Nippon Medical School, Tokyo, Japan
eDepartment of Neurosurgery, Kyorin University, Tokyo, Japan
fDepartment of Neurosurgery, NTT Medical Center Tokyo, Tokyo, Japan
gDepartment of Neuroradiology, Toulouse University Hospital, Toulouse, France
hDepartment of Neurosurgery, Kuopio University Hospital, Kuopio, Finland
iInstitute of Clinical Medicine-Neurosurgery, University of Eastern Finland, Kuopio, Finland
jDepartment of Neurosurgery, University of Tampere, Tampere, Finland
kDepartment of Neurosurgery, University of Turku, Turku, Finland
lDepartment of Neuroradiology, Academic Medical Center, Amsterdam, the Netherlands
mDepartment of Biomedical Engineering and Physics, Academic Medical Center, Amsterdam, the Netherlands
nDepartment of Neurosurgery, Academic Medical Center, Amsterdam, the Netherlands 
oDepartment of Neurology, Academic Medical Center, Amsterdam, the Netherlands
pDepartment of Neurosurgery, Radboud University Medical Center, Nijmegen, the Netherlands
qDepartment of Neurology, Haaglanden Medical Center, Den Haag, the Netherlands 
rDepartment of Neurology, Leiden University Medical Center, Leiden, the Netherlands
sDepartment of Radiology, Haaglanden Medical Center, Den Haag, the Netherlands
tDepartment of Neurosurgery, Institute of Neurological Science, Glasgow, UK
uDepartment of Neurosurgery, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
Background and purpose Prediction of intracranial aneurysm growth risk can assist physicians in 
planning of follow-up imaging of conservatively managed unruptured intracranial aneurysms. We 
therefore aimed to externally validate the ELAPSS (Earlier subarachnoid hemorrhage, aneurysm 
Location, Age, Population, aneurysm Size and Shape) score for prediction of the risk of unruptured 
intracranial aneurysm growth. 
Methods From 11 international cohorts of patients ≥18 years with ≥1 unruptured intracranial 
aneurysm and ≥6 months of radiological follow-up, we collected data on the predictors of the ELAPSS 
score, and calculated 3- and 5-year absolute growth risks according to the score. Model performance 
was assessed in terms of calibration (predicted versus observed risk) and discrimination (c-statistic).
Results We included 1,072 patients with a total of 1,452 aneurysms. During 4,268 aneurysm-years 
of follow-up, 199 (14%) aneurysms enlarged. Calibration was comparable to that of the 
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Introduction 
The prevalence of unruptured intracranial aneurysms in the 
adult population is around 3%,1 and the number of incidentally 
found intracranial aneurysms is increasing.2 After diagnosis of 
an unruptured intracranial aneurysm, the risk of aneurysm rup-
ture has to be carefully weighed against the risk of complica-
tions from preventive aneurysm treatment. In many patients, 
the risk of treatment complications from preventive treatment 
is estimated to outweigh the risk of aneurysm rupture. In a 
number of these patients, the initial treatment of choice is 
conservative management with follow-up imaging.3 Follow-up 
imaging is often recommended because some aneurysms grow 
during follow-up, indicating aneurysm instability with an in-
creased risk of rupture.4,5 If aneurysm growth is detected during 
follow-up, preventive treatment should be reconsidered.3 How-
ever, current international guidelines lack clear recommenda-
tions regarding the optimal timing for follow-up imaging.6,7
The ELAPSS (Earlier subarachnoid hemorrhage, aneurysm Lo-
cation, Age, Population, aneurysm Size and Shape) score was 
developed to guide clinicians in predicting absolute 3- and 
5-year growth risks per aneurysm, according to six simple pa-
tient- and aneurysm characteristics (Table 1).8 The total score 
ranges from 0 to 40, with a higher score indicating increasing 
3- and 5-year growth risks. The score had accurate calibration 
and modest discrimination. However, since prediction models 
often perform worse in new data than in the development 
data, a prediction score is preferably externally validated before 
it is implemented in clinical practice.9 Therefore, we performed 
a multicenter study to externally validate the ELAPSS score.
Methods
Study population
We obtained individual patient data from 11 cohorts of pa-
tients with unruptured intracranial aneurysm(s) from the fol-
lowing geographic regions: Japan (Toyama, Tokyo, and Ota-
wara), Finland (Tampere, Kuopio, and Turku), the Netherlands 
(Nijmegen, Amsterdam, and the Hague), France (Toulouse), 
United Kingdom (Glasgow), Germany (Mannheim and Düssel-
dorf) (Supplementary Table 1). The Kuopio University Hospital 
also participated in the study to develop the ELAPSS score,8 but 
for the validation study a more recent and not previously anal-
ysed patient cohort was used.
Inclusion and exclusion criteria
Following the criteria of the previous study,8 we included co-
horts with consecutive patients ≥18 years with ≥1 unruptured 
saccular intracranial aneurysm with ≥6 months of radiological 
follow-up by means of magnetic resonance angiography, com-
puted tomography angiography, or calibrated digital subtrac-
tion angiography. Extradural aneurysms, fusiform aneurysms, 
or aneurysms that were part of an arteriovenous malformation 
were excluded.
Data collection
The following variables were retrieved by the local investiga-
tors. At time of aneurysm detection: date of first imaging, age, 
sex, history of subarachnoid hemorrhage, aneurysm location, 
and aneurysm size and shape; and during follow-up: occur-
rence of aneurysm growth, date of first imaging with aneurysm 
growth, date of last imaging without aneurysm growth, occur-
rence of rupture, date of rupture, and date of last imaging as-
sessment. Aneurysm size was assessed by the local investiga-
tors or retrieved from radiologic reports on 0.1 to 1 mm scales, 
depending on local facilities. The local investigators also as-
sessed aneurysm shape. Irregular aneurysm shape was defined 
as multiple lobes, blebs or wall protrusions. 
Outcome assessment
Aneurysm growth was defined as growth in one direction of ≥1 
mm or an indisputable change in aneurysm shape on follow-
development cohort with the overall observed risks within the range of the expected risks. The 
c-statistic was 0.69 (95% confidence interval [CI], 0.64 to 0.73) at 3 years, compared to 0.72 (95% 
CI, 0.68 to 0.76) in the development cohort. At 5 years, the c-statistic was 0.68 (95% CI, 0.64 to 
0.72), compared to 0.72 (95% CI, 0.68 to 0.75) in the development cohort.
Conclusions The ELAPSS score showed accurate calibration for 3- and 5-year risks of aneurysm 
growth and modest discrimination in our external validation cohort. This indicates that the score is 
externally valid and could assist patients and physicians in predicting growth of unruptured 
intracranial aneurysms and plan follow-up imaging accordingly. 
Keywords Unruptured intracranial aneurysm; Risk factors; Aneurysm growth; Model validation; 
Subarachnoid hemorrhage; Prevention
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up imaging. Because aneurysm growth is thought to be an ir-
regular process with periods of stability followed by periods of 
slow or rapid growth, it is not possible to determine the exact 
time of aneurysm growth.10 The time of aneurysm growth was 
estimated as the time point halfway between the last imaging 
prior to aneurysm growth and the first imaging with aneurysm 
growth. Follow-up data for patients were censored at the time 
of aneurysm growth, at the time of the last imaging assess-
ment before surgical or endovascular treatment or rupture, or 
at the time of the last imaging assessment during follow-up.
Approval
The Institutional Review Board of the University Medical Cen-
ter Utrecht decided that no formal approval was needed to 
conduct this study.
Statistical analysis
Data were missing on aneurysm size for 13 aneurysms (<1%). 
These aneurysms were excluded from the analysis. The original 
regression equations were applied to calculate 3- and 5-year 
growth risks for each aneurysm.8 We assessed calibration with 
calibration plots and discriminatory performance of the model 
with the c-statistic with 95% confidence interval (CI). Calibra-
tion at 3 and 5 years was examined by dividing patients in 
quintiles according to their predicted risk. The mean predicted 
risk per quintile group was subsequently plotted against the 
observed risk per quintile group. Calibration over time was as-
sessed across risk groups that were predefined as low-risk (0 to 
9 points on the ELAPPS score), intermediate-risk (10 to 19 
points), and high-risk (≥20 points). Analyses were performed in 
R version 3.4 (R Foundation for Statistical Computing, Vienna, 
Austria). Results are reported in accordance with the Transpar-
ent Reporting of a multivariable prediction model for Individual 
Prognosis Or Diagnosis (TRIPOD) statement.11
Results
Between February 1996 and May 2017, a total of 1,072 pa-
tients with 1,452 aneurysms and 4,268 aneurysm-years of fol-
low-up were followed. Median follow-up time was 2.0 years 
(interquartile range, 1.1 to 4.1). Patient- and aneurysm charac-
teristics at time of aneurysm detection in the development and 
validation cohort are shown in Tables 2 and 3. Patients in the 
validation cohort were younger than patients in the develop-
ment cohort and were less often Japanese.
Aneurysm growth was observed in 199 aneurysms (14%) in 
155 patients (14%). Growth rates were comparable to those in 
the development cohort (Figure 1). Aneurysm rupture occurred 
in 14 patients (1.3%). In 10 of these 14 patients (71%) with 
aneurysm rupture, growth was detected before rupture. 
Calibration at 3 years showed that the ELAPSS score slightly 
underestimated growth risk, in particular in the lowest risk 
quintile, but overall observed risks were within the range of the 
expected risks (Figure 2A). For calibration at 5 years again ob-
served risks were within the range of the expected risk, but 
some underestimation occurred in patients in the lowest-risk 
quintile, and an overestimation occurred in the highest risk 
quintile (Figure 2B). Calibration across ELAPSS risk categories 
over time was accurate, but 5-year growth risk was somewhat 
Table 1. The ELAPSS score for prediction of risk of aneurysm growth
Aneurysm growth risk score Points
Earlier subarachnoid hemorrhage
Yes 0
No 1
Location of the aneurysm
ICA/ACA/ACOM 0
MCA 3
PCOM/Posterior circulation 5
Age (yr)
≤60 0
61–65 1
66–70 2
71–75 3
76–80 4
81–85 5
86–90 6
91–95 7
>95 8
Population
North America, China, Europe (other than Finland) 0
Japan 1
Finland 7
Size of the aneurysm (mm)
1.0–2.9 0
3.0–4.9 4
5.0–6.9 10
7.0–9.9 13
≥10.0 22
Shape of the aneurysm
Regular 0
Irregular 4
Reprinted from Backes et al.,8 with permission from Neurology. 
ELAPSS, Earlier subarachnoid hemorrhage, Location of the aneurysm, Age, 
Population, Size and Shape of the aneurysm; ICA, internal carotid artery; 
ACA, anterior cerebral artery; ACOM, anterior communicating artery; MCA, 
middle cerebral artery; PCOM, posterior communicating artery.
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underestimated in the low- and intermediate-risk categories 
(Figure 3). Supplementary Figure 1 shows observed growth 
risks in the development and validation cohort according to 
ELAPSS risk categories. Higher growth risks were observed in 
the low- and intermediate-risk categories in the validation co-
hort compared to the development cohort. 
The c-statistic at 3 years was 0.69 (95% CI, 0.64 to 0.73), 
compared to 0.72 (95% CI, 0.68 to 0.76) in the development 
cohort, and at 5 years 0.68 (95% CI, 0.64 to 0.72), compared to 
0.72 (95% CI, 0.68 to 0.75) in the development cohort.
Table 2. Patient characteristics at time of aneurysm detection for the previously reported development cohort8 and the current validation cohort
Patient characteristic
Development cohort8 Validation cohort
Growth
(n=257)
No growth
(n=1,250)
Total
(n=1,507)
Growth
(n=155)
No growth
(n=917)
Total
(n=1,072)
Female sex 175 (68) 876 (70) 1,052 (70) 120 (77) 676 (74) 796 (74)
Mean age (yr) 63 (20–97) 60 (18–91) 61 (18–97) 56 (19–89) 56 (19–85) 56 (19–89)
≤40 13 (5) 71 (6) 84 (6) 16 (10) 88 (10) 104 (10)
41–50 31 (12) 199 (16) 230 (15) 34 (22) 203 (22) 237 (22)
51–60 60 (23) 350 (28) 410 (27) 44 (28) 279 (30) 323 (30)
61–70 66 (26) 348 (28) 414 (28) 40 (26) 248 (27) 288 (27)
71–80 66 (26) 219 (18) 285 (19) 18 (12) 89 (10) 107 (10)
>80 21 (8) 63 (5) 84 (6) 3 (2) 10 (1) 13 (1)
Earlier subarachnoid  
hemorrhage
21 (8) 232 (19) 253 (17) 19 (12) 213 (23) 232 (22)
Multiple unruptured  
aneurysms
81 (32) 232 (19) 313 (21) 42 (27) 243 (27) 285 (27)
Geographical region
Finland 38 (15) 112 (9) 150 (10) 21 (14) 188 (21) 209 (20)
Japan 148 (58) 576 (46) 724 (48) 6 (4) 78 (9) 84 (8)
Other 71 (28) 562 (45) 633 (42) 128 (83) 651 (71) 779 (73)
Values are presented as number (%) or mean (range). Means were chosen to facilitate comparison with the ELAPSS (Earlier subarachnoid hemorrhage, aneu-
rysm Location, Age, Population, aneurysm Size and Shape) development article.
Table 3. Aneurysm characteristics at time of aneurysm detection for the previously reported development cohort8 and the current validation cohort
Aneurysm characteristic
Development cohort8 Validation cohort
Growth
(n=267)
No growth
(n=1,642)
Total
(n=1,909)
Growth
(n=199)
No growth
(n=1,253)
Total
(n=1,452)
Mean size (mm) 5.5 (1.0–31.4) 3.8 (1.0–32.9) 4.0 (1.0–32.9) 5.8 (1.0–26.6) 4.1 (1.0–50.0) 4.3 (1.0–50.0)
1.0–2.9 61 (23) 687 (42) 748 (39) 50 (25) 469 (37) 519 (36)
3.0–4.9 95 (36) 641 (39) 736 (39) 48 (24) 447 (36) 495 (34)
5.0–6.9 48 (18) 203 (12) 251 (13) 43 (22) 194 (16) 237 (16)
7.0–9.9 32 (12) 82 (5) 114 (6) 32 (16) 104 (8) 136 (9)
≥10.0 31 (12) 29 (2) 60 (3) 26 (13) 39 (3) 65 (5)
Location
ACA/ACOM 39 (15) 306 (19) 345 (18) 49 (25) 245 (20) 294 (20)
PCOM 36 (14) 142 (9) 178 (9) 16 (8) 77 (6) 93 (6)
ICA 59 (22) 490 (30) 549 (29) 49 (25) 313 (25) 362 (25)
MCA 90 (34) 548 (33) 638 (33) 64 (32) 516 (41) 580 (40)
Posterior circulation 43 (16) 156 (10) 199 (10) 21 (11) 102 (8) 123 (9)
Irregular shape 64 (24) 192 (12) 256 (13) 61 (31) 180 (14) 241 (17)
Values are presented as mean (range) or number (%). Means were chosen to facilitate comparison with the ELAPSS (Earlier subarachnoid hemorrhage, aneu-
rysm Location, Age, Population, aneurysm Size and Shape) development article.
ACA, anterior cerebral artery; ACOM, anterior communicating artery; PCOM, posterior communicating artery; ICA, internal carotid artery; MCA, middle cerebral artery.
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Discussion
In this validation study, we found that the ELAPSS score 
showed accurate calibration for 3- and 5-year risks of aneu-
rysm growth, comparable to that in the development study.8 
Discrimination was modest but also comparable to that of the 
development study, making the score overall an externally valid 
tool with modest discriminative power. 
Our findings are in line with a recent study that found in-
creasing ELAPSS score to be associated with aneurysm growth 
in a cohort of 353 patients with 431 unruptured intracranial 
aneursyms.12 The reason for the underestimation of the 5-year 
growth risk for low-risk aneurysms in our validation cohort 
may be in part because median follow-up time in the valida-
tion cohort was only 2.1 years, which limits reliability of the 
Kaplan-Meier estimated observed probabilities at 5 years. Un-
derestimation could also result from factors not included in the 
model. Several aggregate data meta-analyses have identified 
risk factors for aneurysm growth in addition to the risk factors 
included in the ELAPSS score, such as sex, hypertension, smok-
ing, and aneurysm multiplicity.13,14 However, in the develop-
ment of the ELAPSS score, sex and hypertension were discarded 
Figure 1. Cumulative risk of aneurysm growth in development and validation cohort.
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Figure 2. Calibration plots: predicted and observed (A) 3-year and (B) 5-year growth risk. Dots represent observed probabilities and bars the corresponding 
95% confidence intervals, grouped according to quintiles of predicted probabilities.
O
bs
er
ve
d 
3-
ye
ar
 g
ro
w
th
 ri
sk
Predicted 3-year growth risk
0.5
0.4
0.3
0.2
0.1
0.0
0.0 0.1 0.2 0.3 0.4 0.5
O
bs
er
ve
d 
5-
ye
ar
 g
ro
w
th
 ri
sk
Predicted 5-year growth risk
0.5
0.4
0.3
0.2
0.1
0.0
0.0 0.1 0.2 0.3 0.4 0.5A B
Vol. 21 / No. 3 / September 2019
https://doi.org/10.5853/jos.2019.01277 http://j-stroke.org 345
as predictors because of their limited predictive value. Aneu-
rysm multiplicity carries a higher patient risk of growth, but 
this is probably because of the multiple hit risk.15 Smoking is an 
important risk factor for aneurysm growth that should be 
weighed in clinical decision-making, but could not be included 
in the present prediction model because of lack of data in the 
parent cohorts of the development study. Since patients may 
start or quit smoking during follow-up, or increase or decrease 
the number of cigarettes per day over time, the exact impact 
of smoking on aneurysm growth is difficult to assess. 
This study has some limitations that need to be addressed. 
First, because management of the patients was not according 
to a pre-specified protocol, indication for and timing of aneu-
rysm follow-up were determined by the local treating physi-
cians, and thus varied between and within the cohorts, as it 
was the case in the ELAPSS development study. Moreover, an-
eurysms with a very high growth risk were probably treated 
and therefore did not contribute to follow-up. Similarly, pa-
tients with a limited life expectancy due to advanced age or 
comorbidity often do not undergo follow-up imaging. There-
fore, this risk score can only be applied to patients in whom it 
is decided to perform a wait-and-scan policy. Second, mea-
surements were done by the local investigators of the partici-
pating centers, mostly without double data entry or evaluation 
of interobserver agreement, again similar to how this was done 
in the study underlying the development of the ELAPSS score. 
Furthermore, we included different imaging modalities. These 
are limitations for the outcome measurement, but on the other 
hand increase the external validity of our results. 
It remains to be investigated if the discriminative performance 
of the model can be improved by including other parameters. 
Examples may be smoking status, population differences not ac-
counted for by the model, novel imaging parameters like gado-
linium enhancement of the aneurysm wall on magnetic reso-
nance imaging,16 or other, still unknown risk factors. Also, in or-
der to formulate recommendations on the ideal time intervals 
for repeated imaging, a cost-effectiveness analysis should be 
performed. As shown in a recent study,17 no follow-up imaging 
may be indicated for small, low-risk aneurysms. 
Conclusions
The ELAPSS score showed accurate calibration for 3- and 5-year 
risks of aneurysm growth and modest discrimination in our ex-
ternal validation cohort. This indicates that the score is externally 
valid and could assist patients and physicians in predicting 
growth of unruptured intracranial aneurysms and plan follow-up 
imaging accordingly.
Supplementary materials
Supplementary materials related to this article can be found 
online at https://doi.org/10.5853/jos.2019.01277.
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Supplementary Figure 1. Cumulative observed growth risks in development 
and validation cohort according to low-, moderate-, and high-risk catego-
ries of the ELAPSS (Earlier subarachnoid hemorrhage, aneurysm Location, 
Age, Population, aneurysm Size and Shape) score. Cumulative observed 
growth risk in validation cohort (solid line) and development cohort (dotted 
line) across risk categories of the ELAPSS score (low, ≤9; moderate, 10 to 
19; high ≥20). 
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